Prostate-specific membrane antigen (PSMA)–ligand PET imaging provides unprecedented accuracy for whole-body staging of prostate cancer. As PSMA-ligand PET/CT is increasingly adopted in clinical trials and routine practice worldwide, a unified language for image reporting is urgently needed. We propose a molecular imaging TNM system (miTNM, version 1.0) as a standardized reporting framework for PSMA-ligand PET/CT or PET/MRI. miTNM is designed to organize findings in comprehensible categories to promote the exchange of information among physicians and institutions. Additionally, flowcharts integrating findings of PSMA-ligand PET and morphologic imaging have been designed to guide image interpretation. Specific applications, such as assessment of prognosis or impact on management, should be evaluated in future trials. miTNM is a living framework that evolves with clinical experience and scientific data.

前列腺特异性膜抗原（PSMA）配体PET成像为前列腺癌的全身分期提供了前所未有的准确性。随着PSMA配体PET / CT在世界范围内的临床试验和常规实践中越来越多地被采用，迫切需要一种用于图像报告的统一语言。我们提出了分子成像TNM系统（miTNM，版本1.0）作为PSMA配体PET / CT或PET / MRI的标准化报告框架。miTNM旨在组织可理解类别的发现，以促进医师和机构之间的信息交换。此外，已经设计了整合PSMA-配体PET和形态学成像结果的流程图，以指导图像解释。具体应用，如预后评估或对管理的影响，应在以后的试验中进行评估。